diabetic retinopathy — TargetMol Chemicals

Cat No.	Product Name	Synonyms	Targets
T7042	1,5-Isoquinolinediol		PARP
	1, 5-Isoquinolinediol is an inhibitor of poly(ADP-ribose) synthetase (PARP1; IC50: 0.39 μM). The poly(ADP-ribose) polymerases (PARPs) form a family of enzymes with roles in DNA repair and apoptosis. 1, 5-Isoquinolinediol...		PARP
T3803	Specnuezhenide	Nuzhenide,Nuezhenide	Others , NF-κB , Wnt/beta-catenin
	Specnuezhenide (Nuezhenide) significantly protects human neuroblastoma SH-SY5Y cells from 6-hydroxydopamine-induced neurotoxicity.Nuezhenide is the main inhibitory compound of fruits, it shows a clear inhibitory effect t...		Others , NF-κB , Wnt/beta-catenin
T25340	Diprotin A	Ile-Pro-Ile	DPP-4
	Diprotin A (Ile-Pro-Ile) (Ile-Pro-Ile) is a dipeptidyl peptidase IV (DPP-IV) inhibitor.		DPP-4
T36196	CAY10746		ROCK
	CAY10746 is a selective Rho kinase (ROCK) inhibitor that inhibits ROCK I and ROCK II with IC50 values of 0.014 μM and 0.003 μM, respectively.CAY10746 can be used to study diabetic retinopathy.		ROCK
T26326	VU0285655-1	VU-0285655,VU0285655,BML 280,VU 0285655,BML280,BML-280	TNF , Phospholipase , Interleukin
	VU0285655-1(BML-280) is a potent and selective phospholipase D2 (PLD2) inhibitor that inhibits the proliferation of PLD2-deficient cells.VU0285655-1 has an inhibitory effect on high glucose-induced caspase-3 cleavage and...		TNF , Phospholipase , Interleukin
T4S0969	Obtusifolin		Antioxidant , NF-κB
	1. Obtusifolin has antioxidant properties and improves chemically induced diabetes and its complications by modulation of oxidative stress. 2. Obtusifolin suppresses phthalate esters-mediated bone resorption, thus may be...		Antioxidant , NF-κB
T23757	Ascorbic acid, rutoside drug combination	Rutinoscorbin,Rutascorbin,Ruta C 60,Cerutin
	Ascorbic acid, rutoside drug combination is used for treating diabetic retinopathy.
T61403	Plasma kallikrein-IN-3
	Plasma kallikrein-IN-3, a potent inhibitor ( IC 50 : 0.15 μM) of plasma kallikrein, finds application in research related to hereditary angioedema, diabetic macular edema, and diabetic retinopathy [1].
T27670	JNJ-26076713	JNJ26076713
	JNJ-26076713, an orally active alpha V integrin antagonist, represents a potential therapeutic candidate for the treatment of macular edema, age-related macular degeneration, and proliferative diabetic retinopathy.
TN5942	Dammarenediol II	Dammar-24-ene-3,20-diol
	Dammarenediol II may have the ability to prevent diabetic microvascular complications, including diabetic retinopathy, it can inhibit vascular endothelial growth factor (VEGF)-induced intracellular reactive oxygen specie...
T72337	Plasma kallikrein-IN-2
	Plasma kallikrein-IN-2, a potent inhibitor of plasma kallikrein (PKal) with an inhibitory concentration (IC) 50 value of 0.1 nM, is utilized in research targeting hereditary angioedema, diabetic macular edema, and diabet...
T74867	UBX1325
	UBX1325, a Bcl-xL inhibitor, enhances apoptosis in senescent cells, serving as an effective anti-aging agent. It holds potential for age-related eye disease research, including diabetic macular oedema (DME), age-related ...
T79059	CXCR4-IN-1		CXCR
	CXCR4-IN-1 (Example C5), with an IC50 of 20 nM, is a potent inhibitor of CXCR4, applicable for the research of various conditions such as cancer, HIV, diabetic retinopathy, and inflammation [1].		CXCR
T82663	CU06-1004	Sac-1004
	CU06-1004 (Sac-1004) is an orally active compound that acts as an endothelial dysfunction blocker. It mitigates endothelial dysfunction by inhibiting hyperpermeability and inflammation. The compound demonstrates efficacy...